Publications

There have been numerous presentations and publications on our technology and on compounds developed using it. Publications related to our pipeline are published below.

Compound

Meeting

Title

Mirvetuximab Soravtansine

Meeting

Title

ESMO 2018

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), with Pembrolizumab in Platinum-Resistant Ovarian Cancer (PROC): Initial Results of an Expansion Cohort from FORWARD II, a Phase Ib Study

ASCO 2018

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate, in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer: Maturing Safety and Activity Profile from the FORWARD II Phase 1b Study

SGO 2018

Initial Safety and Activity Findings from a Phase IB Escalation Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC) in Combination with Pembrolizumab in Platinum-Resistant Epithelial Ovarian Cancer Patients

SGO 2017

Characterization of Folate Receptor Alpha (FRα) Expression in Archival Tumor and Biopsy Samples in a Phase I Study of Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), in Relapsed Epithelial Ovarian Cancer Patients

ASCO 2017

Safety Findings from FORWARD II: a Phase IB Study Evaluating the Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC), Mirvetuximab Soravtansine (IMGN853), in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin (PLD), or Pembrolizumab in Patients with Ovarian Cancer

ASCO 2017

Mirvetuximab Soravtansine (IMGN853), a Floate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC), in Platinum-Resistant Epithelial Ovarian Cancer (EOC) Patients: Activity and Safety Analyses in Phase I Pooled Expansion Cohorts

SITC 2016

Treatment of Tumor Cells with Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), Activates Monocytes Through Fc-FcyR Interaction and Immunogenic Cell Death

ASCO 2016

IMGN853 (Mirvetuximab Soravtansine), a Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC): Single Agent Activity in Platinum-Resistant Ovarian Cancer (EOC) Patients

AACR 2015

Preclinical Evaluation of Mirvetuximab Soravtansine (IMGN853) Combination Therapy in Ovarian Cancer Xenograft Models

AACR 2015

Development and Application of an Immunohistochemistry-Based Clinical Assay for Evaluating Folate Receptor Alpha (FRα) Expression in the Clinical Setting

IMGN779

Meeting

Title

ASH 2018

Maturing Clinical Profile of IMGN779, a Next-Generations CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

EHA 2018

Robust In Vivo Synergy Between the Anti-CD33 ADC IMGN779 and the FLT3 Inhibitor Quizartinib in Human FLT3-ITD AML Models

ASH 2017

IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro, and Prolonged Survival In Vivo

ASH 2017

IMGN779, a Next Generation CD33-Targeting Antibody Drug Conjugate, Demonstrates Initial Antileukemia Activity in Patients with Relapsed of Refractory Acute Myeloid Leukemia

EHA 2017

Designing the Next Generation CD33-Targeting ADC: IMGN779, Selected for Potency, Novel Mechanism and Preclinical Tolerability, with High Activity in Dessiminated AML Models and Multi-Dose Regimens

ASH 2015

IMGN779, a CD33-Targeted Antibody Drug Conjugate (ADC), with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells

AACR 2015

Plasma Pharmacokinetics and Tumor Accumulation in Mice of IMGN779, an Antibody Drug Conjugate for Acute Myeloid Leukemia

EHA 2014

IMGN779: A CD33-Targeted Antibody Drug Conjugate (ADC) Utilizing a Novel DNA Alkylator, NGN462, is Highly Active In Vitro Against Primary Patient AML Cells and In Vivo Against AML Xenografts in Mice

ASH 2014

The Antibody Drug Conjugate (ADC) IMGN779 is Highly Active In Vitro and In Vivo Against Acute Myeloid Leukemia (AML) with FLT3-1TD Mutations

IMGN632

Meeting

Title

ASH 2018

A Phase 1, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

EHA 2016

IMGN632: A Novel Antibody Drug Conjugate (ADC) of a CD123-Targeting Antibody with a Potent DNA-Alkylator is Highly Active in Preclinical Models of AML with Poor Prognosis

ASH 2016

Oral Presentation: A CD123-Targeting Antibody Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow

ASH 2016

IMGN632: An Antibody Drug Conjugate (ADC) of a CD123-Targeting Antibody with a Novel DNA-Alkylating Payload is Highly Active and Prolongs Survival in AML Xenograft Models

Our Pipeline

Our Science

Our Target Indications